Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Int J Mol Sci ; 21(13)2020 Jun 29.
Article in English | MEDLINE | ID: mdl-32610577

ABSTRACT

Aging is an ineluctable law of life. During the process of aging, the occurrence of neurodegenerative disorders is prevalent in the elderly population and the predominant type of dementia is Alzheimer's disease (AD). The clinical symptoms of AD include progressive memory loss and impairment of cognitive functions that interfere with daily life activities. The predominant neuropathological features in AD are extracellular ß-amyloid (Aß) plaque deposition and intracellular neurofibrillary tangles (NFTs) of hyperphosphorylated Tau. Because of its complex pathobiology, some tangible treatment can only ameliorate the symptoms, but not prevent the disease altogether. Numerous drugs during pre-clinical or clinical studies have shown no positive effect on the disease outcome. Therefore, understanding the basic pathophysiological mechanism of AD is imperative for the rational design of drugs that can be used to prevent this disease. Drosophila melanogaster has emerged as a highly efficient model system to explore the pathogenesis and treatment of AD. In this review we have summarized recent advancements in the pharmacological research on AD using Drosophila as a model species, discussed feasible treatment strategies and provided further reference for the mechanistic study and treatment of age-related AD.


Subject(s)
Alzheimer Disease/drug therapy , Alzheimer Disease/physiopathology , Aging/physiology , Amyloid beta-Peptides/metabolism , Amyloid beta-Peptides/physiology , Animals , Disease Models, Animal , Drosophila melanogaster/metabolism , Humans , Neurofibrillary Tangles/drug effects , Neurofibrillary Tangles/metabolism , Pharmacological Phenomena/drug effects , Pharmacological Phenomena/physiology , Plaque, Amyloid/pathology , tau Proteins/metabolism
2.
Exp Gerontol ; 95: 54-62, 2017 09.
Article in English | MEDLINE | ID: mdl-28457986

ABSTRACT

Effective approaches for drug development involve the repurposing of existing drugs which are already approved by the FDA. Aspirin has been shown to have many health benefits since its discovery as a nonsteroidal anti-inflammatory drug (NSAID) to treat pain and inflammation. Recent experiments demonstrated the longevity effects of aspirin in Drosophila, but its mechanism remains to be explored. In order to elucidate the effects of drug on metabolism, we carried out the metabolic analysis of aspirin-treated flies. The results identified 404 active metabolites in addition to the extended lifespan and improved healthspan in fly. There were 28 metabolites having significant changes between aspirin-treated group and the control group, out of which 22 compounds were found to have detailed information. These compounds are reported to have important functions in energy metabolism, amino sugar metabolism, and urea metabolism, indicating that aspirin might be playing positive roles in the fly's lifespan and healthspan improvement. Because of the conservation of major longevity pathways and mechanisms in different species, the health benefits of aspirin administration could be extended to other animals and humans as well.


Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Aspirin/pharmacology , Drosophila melanogaster/drug effects , Energy Metabolism/drug effects , Longevity/drug effects , Metabolome/drug effects , Animals , Dose-Response Relationship, Drug , Drosophila melanogaster/metabolism , Metabolomics/methods , Oxidative Stress/drug effects , Time Factors
3.
J Gerontol A Biol Sci Med Sci ; 72(10): 1334-1341, 2017 Oct 01.
Article in English | MEDLINE | ID: mdl-28025308

ABSTRACT

The search for antiaging drugs is a key component of gerontology research. A few drugs with positive effects on life span in model organisms have been found. Here, we report that 2,5-dimethyl-celecoxib, a derivative of the anti-inflammatory drug celecoxib, can extend Drosophila life span and delay aging by a mechanism involving insulin signaling and target of rapamycin signaling. Importantly, its positive effects were apparent when the treatment window was restricted to the beginning of life or the later half. 2,5-Dimethyl-celecoxib-induced longevity was also associated with improvements in physical activity, intestinal integrity, and increased autophagy. In addition, 2,5-dimethyl-celecoxib exhibited protective effects against several kinds of stress such as starvation and heat. The generally positive effects of 2,5-dimethyl-celecoxib on both health and life span, combined with its mode of action via evolutionarily conserved signaling pathways, indicate that it has the potential to become an effective antiaging drug.


Subject(s)
Drosophila Proteins/metabolism , Drosophila/physiology , Insulin/metabolism , Longevity/drug effects , Pyrazoles/pharmacology , Sulfonamides/pharmacology , TOR Serine-Threonine Kinases/metabolism , Animals , Blotting, Western , Gene Expression , Phenotype , Signal Transduction
SELECTION OF CITATIONS
SEARCH DETAIL
...